Member Info for Laura2022

Very many thanks LOTM

I note someone says something about £1.93 by 13th Ocotber

Is £1.93 the "all things being equa figure " for a new investor such a myself who hasn't previously owned SNYT

All things considered is this 230p share price undervaluing the shares even with th nil paid ones

It said the shares should be 20 x the previous before consolidation so 230p seems very and too low ?

Can someone help me value SYNT please

From the annual report last week which you've probably not even read

Physiomics' approach has been to use its expertise in interpreting pre-clinical and clinical cancer data to help predict when to treat patients and with what dose of drug. This approach relies on advanced analytical techniques, many of which (such as machine learning and neural networks) are in the field of artificial intelligence (AI). To date this work has been funded by two Innovate UK Grants and one NIHR grant 

I'm not sure if you're being deliberately forgetful or obtuse or not

You've bene asking for 6 weeks about A.I and lots of links have been provided from PYC website AND several recent articles

PYC themselves mentioned AI again in the annual report but you chose to believe a comment on Telegram that A.I is 5yrs away and you've sold at 2.5p but never stating so at the time

Time waster

Company has been particularly successful in attracting repeat business this year from clients such as Numab Therapeutics and Bicycle Therapeutics which have helped to offset a reduction in revenues from long-standing client Merck KGaA (although at the time of writing Merck has just signed its first new project with us since 2022).

The Company's clients in this financial year have been located in the USA, UK, EU and Switzerland. In terms of the mix of work, we continue to work across the full spectrum of R&D from discovery to development, though we continue to focus increasingly on translational projects involving assets entering clinical development for the first time. This is particularly exciting, as it raises our profile and can involve exposure to regulatory authorities. The Company continues to work in the immuno-oncology space with several of its clients, and it is anticipated that the industry focus on this treatment approach is likely to continue for some time.

Personalised Medicine

The personalised medicine and digital health space continues to generate significant interest from both investors and healthcare systems. Many start-ups in this area focus on the use of genetic markers or the pattern-recognition capabilities of artificial intelligence applications. However, we believe that there is a significant opportunity in the analysis of existing clinical data to identify better ways to treat patient using existing drugs and procedures.

The Company has developed a tool for personalised dosing, funded mainly by two Innovate UK and one NIHR grant as noted above.

Is the same obd that you've not once posted on ?

Your only 3 posts on PYC since 6th Sept have been very strange

Amica

Please at least read the reasons why revenues were £600k and not the £900k hoped for by reading the April and May updates

And realise that for £2.5mln market value there's likely to be much much hier for year commenced July 2023 and with £700k+ cash

Having looked at corcel they have had more than 5 share consolidations have changed their name from Regency Mines and over 10yrs have lost 99.9% of value and issued over 50 billion shares

Laughable

Yes Kidlington

I list to the VAL Q and A and I don't think she would have said that without good reason

An added bonus to Pyc

Dr Rob Quinn, Interim Chief Executive Officer of Aptamer Group, commented: "We are pleased to be able to support the team at Neuro-Bio with the development of Optimer binders to enable their revolutionary diagnostic for Alzheimer's disease. Optimer binders have proven performance in lateral flow test formats and our success in delivering functional Optimer binders to Neuro-Bio's biomarker facilitates further diagnostic development. With an increasingly aging population and no current tests available for early-stage diagnosis, the advancement of new biomarkers and diagnostics in this field offers hope to the millions of patients and their loved ones worldwide."

Baroness Susan Greenfield, CEO of Neuro-Bio, commented: 'We're delighted to be working with Aptamer Group on this potentially game-changing technology to combat one of the biggest unmet medical needs of our time. It's a further example of UK ingenuity and teamwork for highly innovative and disruptive science.' 

- ENDS -

Outlook

The impact of the Company's strengthened Board is already being felt through the implementation of new marketing activities, collaborations such as with Inaphaea and Beyond Blood and through the proposed expansion of its consulting business into the field of biostatistics. The Company is looking forward to a successful financial year 2024 during which it aims to achieve a new best ever level of total income, generated from its current core business and emerging biostatistics consulting offering.

But you haven't bought PYC at all

You've posted almost for a year on HARL and before that hadn't posted posted for a few yews

Instead you've posted twice on PYC both times with a negative slant

Exactly Ackers

The numbers for year ended June were already stated back in May ? Nearly 5mths ago, since July the momentum has increased with 4 contracts,Merck have come back and there is over £1mln+ pipeline for current year alone

500, 788

When one looks at Knifes posts for 12mths he seems obsessed

Maybe needs help

After hours

Clarets

Don't forget AFTER these results Merck came back on board and spend €500k+ annually ( main reason for the slip to £609k rev) and from today's RNS

For the first time ever, the Company has felt in a position to quantify the value of its pipeline of potential new contracts that could start in the current financial year which remains at over £1m despite four opportunities having been converted into signed projects during August. This was facilitated through the implementation of a formal CRM process to manage and track opportunities.

The Company is looking forward to a successful financial year 2024 during which it aims to achieve a new best ever level of total income, generated from its current core business and emerging biostatistics consulting offering.